Saturday, November 15, 2014

Are you interested in purchasing an existing publicly traded company?







1. Never been a shell company, free trading
2. Will do terms. Low down
3. low monthly payments.
4. There was a reverse merger done.



Date of original incorporation July 15th 1998
State of incorporation Nevada
Date of Re-Incorporation August 23 2010

State of Re-Incorporation Delaware
Listed as a shell company: No
DTC eligible:
Company financials are current
Taxes due: No
Assets: 0 upon transfer
Liabilities $ 300 K to former owners who will work with new owners to fund
All books and records: Yes
15C211 filed: Yes
Clean: Yes
SEC Reporting status: Non reporting
Market for publicly-Traded securities: OTC Pink Sheets (Caveat Emptor-Was assigned due to reverse merger)


Existing Securities Profile

1) Common Authorized : 74,000,000,000
Common I & O : 5,239,825
Restricted 3,009,013
Float 2,230,812
Authorized Pref A: 100,000,000
   A issued and out: 2,200,000
Authorized Pref B: 200,000,000
   B issued and out: 21,351,750
 Authorized Pref C: 200,000,000
   C issued and out: 0



Monday, November 3, 2014

Buyer paying $1B for Black Eagle 27500











We have a Buyer paying $1B for one or more Black Eagle 27500 from reliable source:

 1. Serial # of the Black Eagle IS to be provided FIRST.
2. The Serial # is checked to confirm legitimacy.
3. AFTER confirmation OF legitimacy 



Serious sellers contact us with requisite serial number of the black eagle after which steps 4 through 10 will be made available.

Sunday, September 21, 2014

US. Dollar provider in Hong Kong is looking for a Euro Provider











We have a U.S. Dollar Provider in Hong Kong looking to exchange with a Euro Provider in a 15/10 Transaction. Here are the particulars.

1. $1 Trillion to $5 Trillion.

2. 15/10 to the Euro Provider.

3. Ledger to Ledger in Standard Chartered Bank, Hong Kong.

4. 1.25% available for Euro Side Intermediaries.

Saturday, September 6, 2014

Information About the Drug Industry and the Agencies That Control It
















In my opinion it's possible, if not likely, that we’ll get more whistleblowers coming out and admitting they covered up vaccine damage.

 

In order to help prepare the ground, a little education is in order.

 

The intention is to sweep aside the vaccine propagandists whose main thrust is that the US medical system is excellent, just fine, science is succeeding on all fronts, so why should we doubt vaccines; don't worry, be happy.

 

In the wake of the CDC whistleblower scandal, many such "defenders of the realm" have emerged.

 

Expressing generalized outrage and disbelief, they assure us that no doctor or healthy agency would do great harm to the population.

 

They tell us that modern medicine, in all its aspects, is wondrous….

 

They assure us that whatever the whistleblower, William Thompson, is saying about published research fraud and vaccines---well, it's simply wrong. All is well. Rainbows and marshmallows.

 

How little they know or care.

 

Documents within the privileged halls of the medical establishment prove them wrong.

 

First and foremost among these documents is Dr. Barbara Starfield's stunning July 26, 2000, review, published in the Journal of the American Medical Association: "Is US health really the best in the world?"

 

Proper and elite credentials were crisply present and accounted for, all the way along the line. Journal of the American Medical Association. Dr. Starfield was a widely respected public health expert, working at the Johns Hopkins School of Public Health.

 

Her conclusions?

 

Every year, in the US, the medical system kills 225,000 people. That's 2.25 MILLION killings per decade.

 

Of these, FDA-approved medical drugs kill 106,000 Americans per year. That's a MILLION killings per decade.

 

In a 2009 interview with Dr. Starfield, she stated that, since her July 2000 publication, other researchers have pegged the death figures even higher.

 

If you Google "FDA, Why Learn About Adverse Drug Reactions," you will see, on the FDA's own website, a page where the annual 100,000-death figure is confirmed.

 

Of course, the FDA takes absolutely no responsibility for this horrific fact. Being the sole US agency in charge of certifying drugs as safe, when those drugs kill 100,000 Americans per year...the FDA's conscience doesn't waver an inch. To put it another way: what conscience?

 

Want more?

 

The citation is: BMJ June 7, 2012 (BMJ 2012:344:e3989). Author, Jeanne Lenzer.

 

Lenzer refers to a report by the Institute for Safe Medication Practices: "It calculated that in 2011 prescription drugs were associated with two to four million people in the US experiencing 'serious, disabling, or fatal injuries, including 128,000 deaths.'"

The report called this "one of the most significant perils to humans resulting from human activity."

 

And here is the final dagger. The report was compiled by outside researchers who went into the FDA's own database of "serious adverse [medical-drug] events."

 

Given what I've written here so far, alert readers will begin to wonder: how can these medical drugs kill so many people, when medical journals report, in thousands of published studies, that the drugs are safe?

 

Ah yes: reliance on published drug-studies.

 

The gold standard. This is what "the professionals" point to when challenged. This is the basis of their "science."

 

It's all a ruse. The published studies declaring the drugs safe are frauds. An insider among insiders confirms this.

 

For 20 years, Dr. Marcia Angell was the editor of one of the most prestigious journals in the world; The New England Journal of Medicine.

 

On January 15, 2009, the NY Review of Books published Dr. Angell's devastating assessment of medical literature:

 

"It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine." -(Marcia Angell, MD, "Drug Companies and Doctors: A story of Corruption." NY Review of Books, Jan. 15, 2009.)

 

Here is another quote of a similar nature, also published in the NY Review of Books (May 12, 2001, Helen Epstein, "Flu Warning: Beware of Drug Companies"):

 

"Six years ago, John Ioannidis, a professor of epidemiology at the University of Ioannina School of Medicine in Greece, found that nearly half of published articles in scientific journals contained findings that were false."

 

Here's another quote from the same article:

 

"Last year, GlaxoSmithKline's diabetes drug Avandia was linked to thousands of heart attacks, and earlier in the decade, the company's antidepressant Paxil was discovered to exacerbate the risk of suicide in young people. Merck's painkiller Vioxx was also linked to thousands of heart disease deaths. In each case, the scientific literature gave little hint of these dangers."

 

And finally, here is yet another statement from Marcia Angell, former editor of The New England Journal of Medicine: "A review of seventy-four clinical trials of antidepressants, for example, found that thirty-seven of thirty-eight positive studies [that praised the drugs] were published. But of the thirty-six negative studies, thirty-three were either not published or published in a form that conveyed a positive outcome."

 

It turns out that the informational pipeline that feeds the entire perception of pharmaceutical medicine is a rank fraud.

 

So...when CDC whistleblower William Thompson made a public statement, on August 27, admitting he and his co-authors cooked and buried vital data in a 2004 Pediatrics study on the MMR vaccine and autism, and when shocked observers rushed to claim there was really no problem and "the official science" was safe and true and good and right, and the CDC was innocent of wrongdoing and it was all a tempest in a teacup, they were entirely ignorant of the big picture, or they were lying through their teeth.

 

Whistleblower Thompson was merely adding one more footnote about medical fraud to a massive and growing encyclopedia of fraud.

 

The encyclopedia stands, dust-covered, on a remote shelf. The US government, the CDC, other public health agencies, doctors, medical schools, drug companies, and those execrable corporate front men---television media anchors---proceed apace, praising US medical science.

 

Problem? What problem? All is well in fairyland. Rainbows and marshmallows…..

 

Wednesday, August 6, 2014

Interested in taking your company public?








The following may be a better solution to your company's finance and long term funding needs providing your company has the on hand liquid cash to pay for becoming publicly traded as a first step? From our affiliate California based company:


Frankfurt and Berlin and other World Wide Stock Exchanges are definitely a viable alternative and/or supplement to the S-1 IPO Registration or "reverse merger" method of "going public" in the US.
Companies from the US, Canada, Australia, Africa, China, India, Brazil, Chile, etc. have formed Canadian, UK, Swiss or other holding companies to use as a vehicle to list on the Frankfurt and other worldwide exchanges.
We have been taking companies public in the US for about 25 years now, but since 2008, when the US economy started having major problems, and when we first got connected to German investors who funded many US companies for us when others couldn’t, we have come to realize the power of being an “international” player. Given the state of the world, with communication to any part of the world being not only practical but “easy”, we have developed an international community for taking our clients public around the world, taping into sources of money around the world.
Right now we feel the best strategy for going public is not to abandon listing in the US altogether, as we see things improving in a year or two in the US, but to achieve multiple listings on several international exchanges.

We have proprietary “international” solutions which allow you to:

1) Go public in as little as 90 days on a foreign exchange and get funded in as little as another 60 days;
2) Be listed in several countries at once – including the US, without US and SEC rules having jurisdiction over your entire structure. This allows you to take advantage of rules on other exchanges like the German exchanges which allow for immediate free trading stock (no holding period) and no bar on affiliate sales (affiliates can sell immediately and as much as they want);
3) Prevent and eliminate the bad effects that “shorting” by market makers, as is usually the practiced on the US OTC, creates;
4) Hold an attractive price for your stock rather than the penny and sub-penny prices that US OTC stocks often fall to;
5) Keep control of your company. Get funded without dilution beyond a set acceptable amount no matter how much money you raise;
6) Do mergers and acquisitions of other companies without losing control of your company are going beyond a set dilution upon merger or acquisition;
7) Attract private “investors” by creating investment grade securities that are guaranteed to make a profit – yes that’s right – you can guarantee the investment will make a profit;
8) Solve problems you may be having with note holders, existing investors, factors and others;
9) And more.
Right now we can take companies public on any of the US Exchanges or OTC, as well as the Bermuda Stock Exchange, GXG Markets UK exchange in London, the London Stock Exchange and AIM, the Aktietorget Stock Exchange in Sweden, the Cypress Stock Exchange, the Vienna Stock Exchange, the German Stock Exchanges – Frankfurt, Berlin, and Stuttgart , – the Toronto Stock Exchange in Canada, the Dubai Stock Exchange, The Singapore Stock Exchange, and the Hong Kong Stock Exchange.
All of the above stock exchanges can provide liquidity to a public company listed there. Which exchanges you should list on first depends on the type of company you have and the particular strategy we would work out for you.

The main advantages of a multi-national listing approach are that you are no longer reliant on any one country or economy. By taping into multiple exchanges you are hedged against sudden negative events in the public sector such that have recently happened in both the US and Germany.

Once you get listed on one exchange, you raise money which then funds a listing on another higher and more prestigious exchange. Once you get listed on the first exchange, it then also becomes an easy matter to get a dual listing on multiple exchanges as another way to raise initial funds.

Going public in the US is still a good and relatively cheap alternative. However US listing take longer than most other countries. A listing on the OTC can take nine to twelve months to achieve.

Listings on many other international exchanges can be had in as little as one to four months. Dual listings on German exchanges, which have liquidity comparable to the US OTC, can be achieved in as little as three to four months.

What we usually recommend is getting listed on a fast exchange, such as GXG or Bermuda, which can then lead to a quick dual listing in Germany. After obtaining funding in Germany, one should expand into and raise money on other international exchanges so that your company is set up to always be in a liquid money raising market in the future.
Costs for going public in the US or on other exchanges can be as little as $25,000 to $75,000 out of pocket for legal, accounting and filing fees. It depends on your company, the country and exchange we are filing on and what you are doing. On average it costs about $75,000 - $90,000 out of pocket expenses plus stock in your company to go public. Sometimes we can provide investors to cover some of these costs. However, investors always want you to have something invested in the endeavor so even with an investor that we might provide you should plan on coming up with at least $25,000 minimum out of your pocket.

Shell companies, existing public companies with no business in them, can also be acquired in most countries for those who are in a hurry. Shell transactions can sometimes be closed in a matter of weeks as opposed to months. Shells range in cost from about $150,000 to $500,000 depending on the exchange you are interested in. If you have that kind of budget and are interested in a shell transaction let us know and we will get back to you with a list of companies that are available for purchase.

FUNDINGS
Initial fundings tend to be through draw down fundings and other market related fundings. We have several broker dealer – US and International – that do firm draw down funding commitments from $1 million on up. We have other firms that will buy blocks of stock and/or notes from shareholders of listed and trading companies.

We also have several banks that will do loans against stock shortly after you get listed and before you start trading for select companies. After an initial funding the same banks will arrange for fundings via stand by letters of credit or bonds for larger transactions ($ 20 to $100 million).



Tuesday, August 5, 2014

Interested in purchasing an existing publicly traded company that's listed on the US. pink sheets?



Primo Pink

Business Description
develops industry-leading, interactive data visualization software and solutions that help business, scientific and engineering users gain critical insight from all types of data. Acomplete line of software products enhance decision-making by bringing information to life using the latest in graphics, Web-based and interactive technologies on all major computing platforms.
Financial Reporting/Disclosure
Reporting StatusAlternative Reporting Standard
Audited FinancialsAudited
Latest ReportMar 31, 2014 Quarterly Report
Next reportJune 30 Annual Report to be filed 9/15/2014
Filing StatusCurrent on all filings, taxes, regulatory issues
Share structure
199,999,000 common authorized; 97,279,906 issued
1,000 Class B common controls board; 1,000 issued
10,000,000 Preferred authorized, none issued.
Majority owner holds67,011,253 of common; 1,000 of Class B common
Known/friendly shares
Total investorsApprox. 1,000
Stock Transfer AgentYes
DTCC eligibleYes
Auditoryes
CIK
Fiscal Year End6/30
OTC MarketplaceOTC Pink Current
Profile Data
SIC - Industry Classification5045 - Computers, peripherals, and software
Business StatusDevelopment Stage Company a/o Sep 25, 2009
Incorporated In:NV, USA
Year of Inc.1991
Employees10 a/o Feb 19, 2014
ShellNo
Taxes currentYes
NOL carryforwardsYes
Legal issuesNo
CleanYes
Assets
Liabilities










 
DVME

This is a Trading Public company that has never been a shell

They will do Terms
So much down so much a month
Term Sheet



State of Original Incorporation
Delaware
Date of Original Incorporation
Aug 21 2000
State of New Incorporation
N/A
Date of New Incorporation
N/A
Listed as shell
No
DTC Eligible
Yes (but DTC Chill)
Financials Current
No - will be upon close
Taxes Due
No
Legal Issues
No
Assets
0 upon transfer
Liabilities
150k with consultants who will workwith new owners to fund.
All books and records
Yes
15c211 filed
Yes
Clean
Yes
SEC Reporting Status
Non-reporting
Market for Publicly-Traded Securities
OTC Pink Sheets, No Information(Stop Sign)
Existing Securities Profile
1) Existing structure immediately prior to sale shall be:
Common Authorized
21,000,000,000
Common I & 0
9,620,310,000
Restricted
4,730,043,800
Float
4,890,266,200
Authorized Pref A
100,000,000 (Voting rights 80% of vote)
A issued and outstanding
90,000
Authorized Pref B
10,000,000 (20,000 common for 1 B)
B issued and outstanding
400,175
Authorized Pref C
20,000,000 ( 500 common for 1 C)
C issued and outstanding
0
Shares to be delivered upon sale and price
Common
4,730,043,800 (50.00%)
Preferred Series A
90,000 (100%)
Preferred Series B
9,000,000 (90.00%) — after 9,599,825 issuance



 

Monday, July 21, 2014

US based Trust absolutely LOVES anything media related for a loan funding arrangement. Solar, wind farms as well as gas and oil projects as well are also of interest














Of course the Trust must perform standard underwriting and due diligence just like any investor or lender and if the project passes muster, they issue the appropriate credit enhancements backed by cash assets or other commercially valuable collateral which may be readily sold on the open market.
Essentially then we simply can then take the project backed by credit enhancements to our lenders and obtain a debt piece.

The loan may cover 100% of the project costs. The costs of the collateral- credit enhancements range from 2%-7% BUT those costs are TAKEN OUT OF CLOSE, so, THERE ARE NO UPFRONT FEES. There are NO GEOGRAPHIC RESTRICTIONS and NO SIZE LIMITATIONS.
The smallest credit enhancements they've ever issued was $20k!!!
   

Lastly, I might add, this same mechanism may be applied to ANY industry vertical of ANY project size for any project INTERNATIONALLY.  Again, industry specific biographical wherewith is the most important criteria, and, even if the management team lacks same, that issue can always be solved by bringing in a third party(ies) which do. Asset builders, solar and wind farm projects have also been identified. Gas and oil projects as well.


Tuesday, July 15, 2014

Paper aset monetizing











 
PAPER ASSETS/CMO's/BOND's/CD's/TREASURIES/MTN’s/STSSTOCKS/NOTES


 
(No Bearer bonds)

NO CREDIT CHECK! NO INCOME DOCUMENTATION! NO APPRAISALS!


If it is not from a Bank or Institution we can not use it.

It also has to be on the Market with Liquidity and Trading value.


NO UPFRONT FEES

FAST CLOSINGS 3 DAYS TO 1 WEEK

Monday, June 23, 2014

Offer 6 units used Airbus A 320-214 PAX YOM for sale





















Offer​ 6 units used Airbus A320-214 PAX YOM
2006 / 2007
​ ​
aircrafts
​for sale ​
stored in Europe and
​ ​
for immediate
delivery .


All aircraft will be delivered with a fresh C-Check, which is included in the price.

The Selling Price is :

1) YOM 2006 is US$ 30 Million per unit .
2) YOM 2007 is US$ 32 Million per unit .


The end seller needs to proceed to receive the LOI with POF and the
10% Deposit by escrow account in USA for the end buyer party to visit the aircraft .

If interested to proceed , we will provide you with NCNDA + Name to put in the LOI
​ .






This​ aircrafts are only for SALE ( NOT for Dry Lease or ACMI or

Lease / Purchase ) .


Saturday, June 14, 2014

Iraqi Dinars wanted













Iraqi Dinars wanted

From US. based attorney:

I represent a Sovereign Buyer interested in buying New Iraqi Dinars.

Larger amounts are preferred

Friday, June 6, 2014

Investment/Ownership in technology company
















USA -$ BANK WILL GUARANTEE FUNDS $

INVESTMENT/OWNERSHIP – RISKLESS - HIGH RETURNS - USA BASED $

ONCE IN A LIFETIME OPPORTUNITY

RETIRE FOR LIFE

OWNERSHIP FOR LIFE


OWNERSHIP INVESTMENT POSITIONS FROM

$250K UP TO - $6MM

WAS $15M –ONLY $6MM AVAILABLE

Investor will receive returns starting in ‘60 Days’ after signing on.

Ask for  document  #1
ANNUAL FINANCIAL SUMMARY - NET INCOME - RETURNS

i.e.

:

Minimum investment of $250K @ .50% = $MM+


Technology Company Ownership


This is a real opportunity to own a BRICK & MORTAR –Up-Running-Operational-riskless investment in the USA –Annual Returns over a Billion.

‘Patented New Technology Company’ in reducing CO2 Emissions & Reducing Fuel Consumption in ‘Combustion Engines’-Automobiles/Trucks/Marine Engines and Generators, up to 70%.

The owner has put in $$$$$$$ Millions of his own money and there are ‘Secured Agreements’ (Off Takes) with GM, Caterpillar, Mercedes Benz just to name a few….and the U.S. MILITARY.

They are currently working in Europe and are now in the USA.

There is a USA Prototype-German & U.S. Patents.

The technology described in the package has been patented since 1997 and has had a fully operational prototype automobile on the road since 1998

There are TWO buildings now owned & operational. The Manufacturing Facility & Offices are located in Southern Alabama, and Rhode Island.

This is NOT a ‘Start-Up’ or for ‘R & D’-Not seeking a loan.

The owner is offering ‘Investors’ a Percentage of Ownership.


 
‘Ownership Positions’ are ‘Limited’ - ‘First Come’ ‘First Served’ $

3 PHASE FINANCIAL PLAN - OFFERING UP TO 30% OWNERSHIP


Each ‘Capital Investment’ from ‘Investor’, will be represented by a percentage of ownership to the ‘Investor’ calculated at a1:2 Ratio.

Ask for document #2
ANNUAL FINANACIAL SUMMARY REVENUES

************************************************************

PROCEDURES:

TOTAL TRANSPARENCY PROVIDED

KYC call with the prospective ‘Investor’.

Non-Disclosure will be issued, signed and returned by the Investor.

Investor will receive the Complete Package- ‘Presentation’ ’Financial Overview’ & ‘Executive Summary’ via Drop Box.

After review, we then can set up a call with the principal.